Results of Major Myeloma Treatment Trial Published in The Lancet
In December, the exciting results of the SWOG clinical trial on myeloma treatment, S0777, were published in The Lancet. The trial showed that the addition of the drug bortezomib to the standard two-drug course of dexamethasone and lenalidomide for multiple myeloma patients significantly lengthened the lives of impacted patients.
CRAB CEO and SWOG biostatistician, Antje Hoering, PhD, and CRAB and SWOG biostatistician, Rachael Sexton, MS, were instrumental in the design and analysis of this trial along with many other SWOG and CRAB personnel. CRAB contributed to the trial with statistical, data management, and technology support as a member of the SWOG Statistics and Data Management Center housed at the Fred Hutchinson Cancer Research Center and CRAB.
CRAB has long enjoyed a successful partnership with SWOG in clinical trial work, and looks forward to great collaborations in 2017. For more information about the publication in The Lancet, please see SWOG’s press release here.
CRAB Co-Founder Honored for Influential Research
CRAB Co-Founder John Crowley, PhD, has once again been recognized as most-influential in the field of clinical medicine. Clarivate Analytics has listed Dr. Crowley as one of its Highly Cited Researchers for 2016. This is the second year in which Dr. Crowley has garnered this distinction, which is given to researchers that have a global impact in their respective fields through their published works. Dr. Crowley and the other honored researchers for 2016 are listed on the award’s official website.
Dr. Crowley is the author of more than 400 peer-reviewed professional papers, and has contributed to and edited several books on the methodology of clinical trials, including Handbook of Statistics in Clinical Oncology, Third Edition and Clinical Trials in Oncology, Third Edition. Dr. Crowley’s affiliation with the University of Washington is highlighted with the Clarivate honor. The University thanked Dr. Crowley in their congratulatory letter to him, for his “incredible contributions to the clinical medicine community.”
Doug Mounce Published and Honored by the SRAI
Judicial interpretation of Food and Drug Administration regulations on clinical trial sponsorship
in cases of injury claims is the focus of a paper co-authored by Doug Mounce, CRAB’s Grants and Contracts Manager, Frank X. Curci, partner at Ater Wynne, LLP, and a member of the CRAB Board of Directors, and Joshua B. Fortenbery, intern at Ater Wynne. The paper, Spotlight on Clinical Trial Sponsorship, was published by the Society of Research Administrators International (SRAI) in the Spring 2016 issue of their Journal of Research Administration. The authors’ goal for the article was to provide some guidance as to what liability is currently associated with assuming the role of “sponsor” in a clinical trial.
Mr. Mounce was also awarded a scholarship to attend the Society of Research Administrators International (SRAI) conference held Oct. 22-26 in San Antonio where he presented a session on clinical trial sponsorship, and a poster based on the paper. We congratulate him for these achievements.